

Ashish Upadhyay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2651456/publications.pdf>

Version: 2024-02-01

26
papers

3,380
citations

567281

15
h-index

552781

26
g-index

26
all docs

26
docs citations

26
times ranked

5624
citing authors

#	ARTICLE	IF	CITATIONS
1	End-stage kidney disease and COVID-19 in an urban safety-net hospital in Boston, Massachusetts. PLoS ONE, 2021, 16, e0252679.	2.5	4
2	Association of Mildly Reduced Kidney Function With Cardiovascular Disease: The Framingham Heart Study. Journal of the American Heart Association, 2021, 10, e020301.	3.7	13
3	CREDESCENCE: Significant Victory for Diabetic Kidney Disease. Trends in Endocrinology and Metabolism, 2020, 31, 391-393.	7.1	5
4	Dialyzer reuse: is it safe and worth it?. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2019, 41, 312-314.	0.9	3
5	Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney International, 2018, 93, 1397-1408.	5.2	83
6	Reuse and Biocompatibility of Hemodialysis Membranes: Clinically Relevant?. Seminars in Dialysis, 2017, 30, 121-124.	1.3	9
7	Ultrapure versus standard dialysate: A cost-benefit analysis. Seminars in Dialysis, 2017, 30, 398-402.	1.3	4
8	We Use Impure Water to Make Dialysate for Hemodialysis. Seminars in Dialysis, 2016, 29, 297-299.	1.3	17
9	Renal Artery Calcium, Cardiovascular Risk Factors, and Indexes of Renal Function. American Journal of Cardiology, 2014, 113, 156-161.	1.6	23
10	Statins in chronic kidney disease: what do meta-analyses tell us?. Clinical and Experimental Nephrology, 2014, 18, 278-281.	1.6	5
11	Is the lower blood pressure target for patients with chronic kidney disease supported by evidence?. Current Opinion in Cardiology, 2012, 27, 370-373.	1.8	5
12	Lipid-Lowering Therapy in Persons With Chronic Kidney Disease. Annals of Internal Medicine, 2012, 157, 251.	3.9	146
13	Lipid-Lowering Therapy in Individuals With CKD: Lessons Learned From SHARP. American Journal of Kidney Diseases, 2012, 59, 170-173.	1.9	7
14	Assessment of Proteinuria. Advances in Chronic Kidney Disease, 2011, 18, 243-248.	1.4	44
15	Systematic Review: Blood Pressure Target in Chronic Kidney Disease and Proteinuria as an Effect Modifier. Annals of Internal Medicine, 2011, 154, 541.	3.9	292
16	Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrology Dialysis Transplantation, 2011, 26, 920-926.	0.7	117
17	Predictors of Incident Albuminuria in the Framingham Offspring Cohort. American Journal of Kidney Diseases, 2010, 56, 852-860.	1.9	48
18	Impact of Hospital-Associated Hyponatremia on Selected Outcomes. Archives of Internal Medicine, 2010, 170, 294.	3.8	429

#	ARTICLE	IF	CITATIONS
19	Multiple Genetic Loci Influence Serum Urate Levels and Their Relationship With Gout and Cardiovascular Disease Risk Factors. <i>Circulation: Cardiovascular Genetics</i> , 2010, 3, 523-530.	5.1	285
20	Arterial Stiffness in Mild-to-Moderate CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 2044-2053.	6.1	127
21	Multiple loci associated with indices of renal function and chronic kidney disease. <i>Nature Genetics</i> , 2009, 41, 712-717.	21.4	553
22	Epidemiology of Hyponatremia. <i>Seminars in Nephrology</i> , 2009, 29, 227-238.	1.6	206
23	Risk of thromboembolism with short-term interruption of warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 116-116.	2.1	1
24	Risk of Thromboembolism With Short-term Interruption of Warfarin Therapy. <i>Archives of Internal Medicine</i> , 2008, 168, 63.	3.8	307
25	Single-Use versus Reusable Dialyzers. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 1079-1086.	4.5	44
26	Incidence and Prevalence of Hyponatremia. <i>American Journal of Medicine</i> , 2006, 119, S30-S35.	1.5	603